论文部分内容阅读
加洛帕米(gallopamil)是维拉帕米的甲基化产物,其抑制钙依赖的兴奋-收缩偶联的效力较维拉帕米强3～5倍。给加洛帕米单剂量50mg具有抗心绞痛的临床效应,但其半衰期较短,仅3.5h,因此开发了一种缓释疗法。本研究目的旨在评价加洛帕米缓释给药法对慢性稳定性心绞痛的疗效及合适的剂量。研究对象为18例有慢性心绞痛史,但已稳定3个月的病人,活动平板运动试验总时间大于3min,小于或等于9min(以ST段水平或倾斜下降1mm为标准)。除舌下含服硝酸甘油外,停用其它抗心绞痛药物2周后,进行单、双盲性研究。病人分为安慰剂组,每日
Gallopamil, a methylated product of verapamil, is 3 to 5 times more potent than verapamil in its inhibition of calcium-dependent excitatory-contractile coupling. Given the clinical effect of a single dose of 50 mg of Galopipram with anti-anginal activity, but with a short half-life of only 3.5 h, a sustained-release therapy was developed. The purpose of this study was to evaluate the efficacy and appropriate dosage of sustained-release galapomil for chronic stable angina. Participants were 18 patients with a history of chronic angina, but who had been stable for 3 months. The total treadmill exercise test was longer than 3 min and less than or equal to 9 min (ST level or 1 mm asleep). In addition to sublingual nitroglycerin, the other anti-anginal drug stopped after 2 weeks, single-and double-blind study. Patients were divided into placebo group, daily